Vutrisiran : Alnylam Pharmaceuticals reveals positive results from HELIOS-B Phase 3 study
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a pioneer in RNA interference (RNAi) therapeutics, has unveiled promising results from the HELIOS-B Phase 3 study of vutrisiran, a ... Read More
Roche, Alnylam’s Zilebesiran meets primary endpoint in KARDIA-1 trial
Breaking news in the world of hypertension treatment, Roche and Alnylam Pharmaceuticals have announced the success of their Phase 2 study KARDIA-1. The investigational RNAi ... Read More
Alnylam, Dicerna form RNAi collaboration for alpha-1 liver disease
Alnylam Pharmaceuticals and Dicerna Pharmaceuticals are joining forces to develop and commercialize ribonucleicacid interference therapies (RNAi therapeutics) for the treatment of alpha-1 antitrypsin deficiency-associated liver ... Read More
Alnylam Pharmaceuticals completes patient enrollment for Phase 3 trial of givosiran in acute hepatic porphyrias
Alnylam Pharmaceuticals has announced the completion of patient enrollment for its pivotal phase 3 trial, ENVISION, which evaluates the efficacy of givosiran in treating acute ... Read More